AMARANTUS BIOSCI INC (OTCMKTS:AMBS) stated that it obtained a Notice of Allowance from the USPTO for U.S. Patent Application 13/305,025 based on Dopaminergic Neuronal Survival. Upon issuance, the new patent will give extra intellectual property cover for MANF cell therapy and protein therapy. The allowed patent includes compositions of matter and procedures of use associated with Amarantus’s proprietary manufacturing methods for synthetic MANF and its treatment.
Amarantus reported that the native MANF is under advancement for the cure of orphan ocular indications, including RP. The company recently obtained orphan drug status for MANF for the RP treatment in the U.S. and in Europe. Moreover, MANF proteins have showed proof-of-concept in preclinical trials to treat numerous conditions including macular degeneration, Parkinson’s disease, retinal artery occlusion, glaucoma, diabetes and ischemic heart disease.
The expert speaks
Amarantus CEO Gerald E. Commissiong said that the notice of allowance is an important milestone achieved as per the company’s intellectual property plan. It will enable company to fully use the fundamental value of the R&D ongoing for MANF. It is being formulated as an effective therapeutic intervention for treatment of particularly orphan ocular diseases. It is also meant for other chronic disorders for which hardly any viable treatment options exist.
The Notice of Allowance highlights Amarantus commitment to strengthening intellectual property portfolio for MANF. The company will continue to expand robust intellectual property to further maintain and protect its proprietary rights, which will allow it to use the existing opportunities in respective MANF segment. It will also establish Amarantus as the pioneering company for significant collaborations.
In last trading session, the stock price of Amarantus declined more than 2% to close the trading session at $0.0479. The decline came at a share volume of 2.40 million compared to an average share volume of 5.89 million.